Dexmedetomidine Pretreatment Attenuates Kidney Injury and Oxidative Stress during Orthotopic Autologous Liver Transplantation in Rats by Xia, Z et al.
Title
Dexmedetomidine Pretreatment Attenuates Kidney Injury and
Oxidative Stress during Orthotopic Autologous Liver
Transplantation in Rats
Author(s) Yu, X; Chi, X; Wu, S; Jin, Y; Yao, H; Wang, Y; Xia, Z; Cai, J
Citation Oxidative Medicine and Cellular Longevity, 2015, v. 2016, p.article no. 4675817
Issued Date 2015
URL http://hdl.handle.net/10722/231628
Rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Research Article
Dexmedetomidine Pretreatment Attenuates
Kidney Injury and Oxidative Stress during Orthotopic
Autologous Liver Transplantation in Rats
Xiaofang Yu,1,2 Xinjin Chi,1 Shan Wu,1 Yi Jin,3 Hui Yao,1 Yiheng Wang,1,4
Zhengyuan Xia,5 and Jun Cai1
1Department of Anesthesiology, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510630, China
2Department of Anesthesiology, Fujian Provincial Hospital, Fuzhou, Fujian 350001, China
3Department of Pathology, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510630, China
4Department of Anesthesiology, First Affiliated Hospital, University of South China, Hengyang, Hunan 421001, China
5Department of Anesthesiology,The SecondAffiliatedHospital &Yuying Children’s Hospital ofWenzhouMedical University,Wenzhou,
Zhejiang 325027, China
Correspondence should be addressed to Zhengyuan Xia; zyxia@hku.hk and Jun Cai; gzcaijun@hotmail.com
Received 4 May 2015; Revised 2 August 2015; Accepted 3 August 2015
Academic Editor: Ryuichi Morishita
Copyright © 2016 Xiaofang Yu et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This paper aims to explore whether pretreatment with dexmedetomidine (Dex) has antioxidative and renal protective effects during
orthotopic autologous liver transplantation (OALT) and its impact on nuclear factor erythroid 2-related factor 2 (Nrf2) activation.
Sprague-Dawley rats were randomized into groups that include sham-operated (group S), model (group M), low dose Dex (group
D1), high dose Dex (group D2), atipamezole (a nonspecific 𝛼
2
receptor blocker) + high dose Dex (group B1), ARC239 (a specific
𝛼2B/c receptor blocker) + high dose Dex (group B2), and BRL-44408 (a specific 𝛼2A receptor blocker) + high dose Dex (group
B3). Then histopathologic examination of the kidneys and measurement of renal function, the renal Nrf2 protein expression, and
oxidants and antioxidants were performed 8 hours after OALT. We found that pretreatment with Dex activated Nrf2 in glomerular
cells and upregulated antioxidants but reduced oxidants (all𝑃 < 0.01, group D2 versus groupM). Atipamezole and BRL-44408, but
not ARC239, reversed these protective effects. In conclusion, pretreatment with Dex activates Nrf2 through 𝛼2A receptor, increases
the antioxidant levels, and attenuates renal injury during OALT.
1. Introduction
Orthotopic liver transplantation (OLT) has been considered
the best choice for end-stage liver diseases [1]. Acute kidney
injury (AKI) is the most common and severe complication
after OLTwith a 12%–70% [2, 3] incidence rate and an annual
mortality rate of up to 35%–45% [4]. It is an important factor
in early postoperative death and influences the prognosis and
rehabilitation of patients [5, 6]. Therefore, it is important to
try to increase the survival rate and improve the rehabilitation
after OLT by means of controlling and/or avoiding acute kid-
ney injury in the perioperative period of liver transplantation.
Previous studies have demonstrated that the oxidative stress
injury is related to AKI after OLT.
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a
master transcriptional factor in cells, which acts against
oxidative and stress injury. It can enhance the antioxidant
enzymes and phase II detoxification enzyme levels in com-
bination with the antioxidant response element (ARE) and
plays a key role in the endogenous antioxidative activity
[7, 8]. Recent studies have borne out claims that it plays
an important role in preventing ischemia-reperfusion injury.
Some researchers have reported that Nrf2 can provide pro-
tective effect by upregulating the expression of heme oxyge-
nase 1 (HO-1), nicotinamide-adenine dinucleotide phosphate
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(NADPH), glutathione reductase (GR), and glutathione per-
oxidase (GPx). But whether the AKI after OLT is associated
with Nrf2 is still uncertain [9–12].
Dexmedetomidine (Dex) is a highly selective alpha 2
adrenergic receptor (𝛼
2
-AR) agonist. Because of its effect on
alpha 2 receptors of the locus ceruleus, Dex can provide an
ideal sedative and analgesic [13–15]. Recently, many studies
have found that Dex protects the heart, brain, and small
bowel. Bell et al. had reported that Dex offers good peri-
operative hemodynamic stability and neuroprotective effects
[16]. Wanga et al. demonstrated that perioperative treatment
with propofol and Dex conferred neuroprotection against
I/R injury in rats, and this protective effect was correlated
with the antioxidant, anti-inflammatory, and antiapoptotic
properties of propofol and/or Dex through a significant
reduction in free radical release and production of proinflam-
matory cytokines, as well as acute reversal of activation of the
apoptosis-related proteins [17].
Those researches about Dex and AKI after OLT are rare;
in particular, no one had reported that the subtype of 𝛼
2
-
AR is related with the protection of the renal function. The
aim of the study was to determine whether pretreatment with
an 𝛼
2
adrenergic receptor activator, Dex, has antioxidative
protective renal effects mediated by Nrf2 during orthotopic
autologous liver transplantation (OALT) in a rat model.
2. Materials and Methods
2.1. Animals. Male Sprague-Dawley (SD) rats, aged 8–10
weeks, weighing 220–250 g,were purchased from theMedical
Experimental Animal Center of Guangdong Province. This
study was performed with the approval of the Institutional
Animal Care and Use Committee of Sun Yat-sen University
in Guangzhou, China, and in accordance with the principles
stated in the Guide for the Care and Use of Laboratory
Animals (National Institutes of Health, 1985). All rats were
housed in individual cages in a temperature-controlled room
with alternating 12 h light/dark cycles. The rats were accli-
mated for one week prior to experiments. Food was withheld
12 h before the start of experiments, but all animals had free
access to water.
2.2. Experimental Groups. Fifty-six rats weighing 220–280 g,
fed by animal feed and raised in 25–27∘C, were randomly
divided into 7 groups with 8 rats/group. Sham-operated
group (S) did not undergo I/R. Model group (M) was
pretreated with normal saline by i.p. injection 30min before
operation. Rats in group D1 received 10 𝜇g/kg Dex (Hengrui
Pharmaceutical Co., Ltd., Jiangsu, China) by i.p. injection
30min before operation. Rats in group D2 received 50 𝜇g/kg
Dex by i.p. injection 30min before operation. Rats in groups
B1, B2, and B3 received 500 𝜇g/kg atipamezole (a nonspecific
𝛼
2
receptor blocker, Sigma-Aldrich, USA), 50 𝜇g/kg ARC239
(a specific 𝛼
2B/c receptor blocker, Santa Cruz, USA), and
1.5mg/kg BRL-44408 (a specific 𝛼
2A receptor blocker, Sigma-
Aldrich, USA) by i.p. injection 40min before receiving
50 𝜇g/kg Dex prior to OALT.
2.3. Construction of Rat OALT Model. A standard model of
OALT was created as previously described [18, 19]. The rats
were fasted for 12 h and anesthetized using 2% inhaled isoflu-
rane (Baxter Healthcare Corporation), which were adminis-
tered through an open face guard, and fixed on the electric
blanket. Following the anesthesia, the abdomen was incised,
exposing themanubrium and xiphoid ensistermum.Thenwe
isolated the liver in anticlockwise direction, the left triangular
ligament of the liverwas resected and the left phrenic veinwas
ligated and disconnected, and we covered the liver with a wet
gauze, opened the retroperitoneum, and isolated the bare area
of liver.The suprahepatic vena cava (SVC) was fully liberated,
and the right suprarenal vein was ligated. Once the liver was
replaced in its original position, the inferior vena cava (IVC)
was dissociated, the first hepatic portal was exposed, and
the portal vein (PV) was separated from the splenic veins
and the convergence of the inferior mesenteric vein. The
hepatic artery and the biliary tract were liberated together
according to their anatomic relationship. Before ischemia, we
injected 1mL heparin saline solution through the caudal vein.
Subsequently, the microvascular clamps were folded on the
convergence of the inferior mesenteric vein, hepatic artery,
splenic vein, SVC, and IVC.The PVwas punctured with a 4th
needle in preparation for reperfusion and a 1mm incisionwas
made in the wall of the IVC as an outflow tract. Ringer lactate
solution (precooled, 0∼4∘C) was injected during reperfusion
at a speed of 2.0mL/min and we cooled the liver with iced
physiological saline at the same time until the liver color
progressively turned yellowwhichmeant the reperfusion was
successful. Finally, after the needle was extracted, the incision
of the PV was closed using 9-0 sutures and the opening of
IVC was repaired by 8-0 sutures.The clamps on the PV, SVC,
IVC, and hepatic artery were loosened and we rewarmed the
liver withwarm saline in themeanwhile.Thewhole anhepatic
phase lasted for 20 ± 1min. We have determined previously
that kidney damage wasmost severe and the level of oxidative
stress highest 8 h after reperfusion, during OALT [19]. For
this reason, the 8 h time point was selected for the current
experiments.
2.4. Collection of the Specimens. Rats received inhalational 1-
2% isoflurane (Baxter Healthcare Corporation) 8 h after OLT
during which 1mL of blood was obtained by cardiac punc-
ture. The sample was centrifuged for 10min at 1500 r/min
and the supernatant stored at −20∘C. The left kidney was
excised and fixed in 4% paraformaldehyde and prepared for
pathological and immunofluorescence analyses.
2.5. Examination of the RenalHistopathology [19]. Thekidney
specimens were embedded in paraffin, cut into 5𝜇msections,
stained with hematoxylin and eosin staining for microscopic
examination, and scored on the pathologic change. The
pathologist was blinded to the protocol.
2.6. Assessment of Kidney Function. Serum creatinine (Scr)
and blood urea nitrogen (BUN) were test in blood sample
with automatic biochemistry analyzer (Olympus AU640).
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Figure 1: Remote kidney damage of rats in various groups after OALT. Kidney sections were stained with hematoxylin and eosin (HE) and
visualized at ×400 magnification. (a) Group S; (b) group M; (c) group D1; (d) group D2; (e) group B1; (f) group B2; and (g) group B3.
2.7. The Expression of Nrf2 by Immunofluorescence Staining.
After dewaxing, samples were heated and then incubated
with 3% hydrogen peroxide. Rabbit monoclonal anti-Nrf2
antibody (Abcam, UK) was added to the slices and incubated
at 4∘C overnight; FITC-labeled goat anti-rabbit IgG anti-
body was added for 2 h and mounted with antifluorescence
quenching coverslip which contained DAPI. Imaging was
performedwith a Zeiss LSM 510 confocalmicroscopic system
[20]. The fluorescence intensity was determined by Image-
Pro Plus version 5.0 system (Media Cybemetics, USA).
2.8. Measurement of Oxidative Indexes, Such as Superox-
ide Dismutase (SOD), Glutathione (GSH), Total Antioxidant
Capacity (T-AOC), Hydrogen Peroxide (H2O2), Hydroxyl Free
Radical (∙OH), and Malondialdehyde (MDA). The contents
of SOD, GSH, T-AOC, H
2
O
2
, ∙OH, and MDA in renal tissue
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Table 1:Theweights of rats and the times of anhepatic phase among
7 groups (the data were represented as mean ± standard deviation
(SD), 𝑛 = 8).
Groups Weight (g) Time of anhepatic phase (min)
Group S 241.3 ± 18.1 —
Group M 240.6 ± 15.0 19.9 ± 0.5
Group D1 234.1 ± 20.3 19.8 ± 0.8
Group D2 240.5 ± 16.8 20.0 ± 0.6
Group B1 243.4 ± 21.6 20.0 ± 0.7
Group B2 243.1 ± 17.5 20.1 ± 0.6
Group B3 239.9 ± 21.0 20.2 ± 0.5
were measured by assay kits (Kaiji Biological Technology
Development Co., Ltd., Nanjing, China).
2.9. Statistical Analysis. Statistical analysis was performed by
using SPSS 12.0 software. Quantitative data were presented
as mean ± SEM. Multiple comparisons among groups were
analyzed by one-way ANOVA.The paired comparisons were
using Fisher’s Least Significant Difference (LSD) Procedure.
All statistical tests were two-sided, and 𝑃 < 0.05 were
considered to be statistically significant.
3. Results
3.1. Characteristics of Rats among Groups. The weight of rats
and the time of anhepatic phase among 7 groups were similar,
as shown in Table 1.
3.2. Remote Kidney Damage in the Groups. As shown in
Figures 1 and 2, compared with group S, the kidney damage
in group M was severe (16.38 ± 4.21 versus 122.38 ± 8.99,
𝑃 < 0.01) and included renal tubular cavity expansion andflat
renal tubular epithelial cells. Missing nuclear staining could
be obviously observed under light microscope. Compared
with group M, the pathological changes and scores of rats
pretreated with Dex, groups D1 (122.38 ± 8.99 versus 7.88 ±
6.53, 𝑃 < 0.01) and D2 (122.38 ± 8.99 versus 56.75 ± 9.71,
𝑃 < 0.01), were significantly lower, especially in group D2
which received 50𝜇g/kg Dex. Compared to group D2, the
protective effect was reversed in group B1 (56.75±9.71 versus
125 ± 11.19, 𝑃 < 0.01) which received atipamezole and in
group B3 (56.75 ± 9.71 versus 124.13 ± 11.36, 𝑃 < 0.01)
which received BRL-44408. There was no effect in group B2
(56.75 ± 9.71 versus 53.25 ± 7.89, 𝑃 > 0.05).
3.3. Changes of Serum Creatinine and Blood Urea Nitrogen
Levels. As shown in Figure 3, compared with group S, the
values of Scr (Figure 3(b)) and BUN (Figure 3(a)) increased
significantly in group M (33.50 ± 5.86 𝜇mol/L versus 74.63 ±
17.89 𝜇mol/L, 𝑃 < 0.01, and 3.43 ± 1.13mmol/L versus
14.00 ± 7.77mmol/L, 𝑃 < 0.01). Compared with group
M, the levels of Scr and BUN were decreased significantly
in D1 (74.63 ± 17.89 𝜇mol/L versus 45.63 ± 17.73 𝜇mol/L,
𝑃 < 0.01, and 14.00 ± 7.77mmol/L versus 7.86 ±
6.47mmol/L, 𝑃 < 0.01) and D2 (74.63 ± 17.89 𝜇mol/L versus
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Figure 2: Pathological scores of kidney tissue. A score from 0 to 3
was given for each tubular profile: 0 = normal histology; 1 = mild
injury: tubular cell dilatation (expanded 50 times its normal size);
2 = moderate injury: epithelial cells which are flattened, moderate
tubular dilatation, or partial nuclear condensation; 3 = severe injury:
the shape of healthy cells lost, with severe tubular dilatation or
nuclear condensation.Thedatawere represented asmean± standard
deviation (SD), 𝑛 = 8. 󳵳𝑃 < 0.01 versus group S; ◼𝑃 < 0.01 versus
group M; X𝑃 < 0.01 versus group D2.
38.69 ± 14.22 𝜇mol/L, 𝑃 < 0.01, and 14.00 ± 7.77mmol/L
versus 5.29 ± 2.75mmol/L, 𝑃 < 0.01). Compared to group
D2, the values of Scr and BUN increased significantly in
group B1 (74.63 ± 17.89 𝜇mol/L versus 69.25 ± 10.66 𝜇mol/L,
𝑃 < 0.01, and 14.00 ± 7.77mmol/L versus 10.29 ± 2.75,
𝑃 < 0.01) and group B3 (74.63 ± 17.89 𝜇mol/L versus 70.75 ±
38.69 𝜇mol/L, 𝑃 < 0.01, and 14.00 ± 7.77mmol/L versus
12 ± 11.74mmol/L, 𝑃 < 0.01). This protective effect was
reversed in group B1 which received atipamezole and group
B3 which received BRL-44408. There was no effect in group
B2 (74.63 ± 17.89 𝜇mol/L versus 36.45 ± 6.37 𝜇mol/L, 𝑃 >
0.05, and 14.00 ± 7.77mmol/L versus 6.86 ± 1.46mmol/L,
𝑃 > 0.05).
3.4. Nrf2 Immunofluorescence Staining and Analyzing. Nrf2
is a transcriptional factor which has been shown to have a
protective effect by decreasing oxidative and stress injury.
Increases in nuclearNrf2 are associatedwith an improvement
in levels of antioxidative and antistress factors of cells, result-
ing in less damage. Immunofluorescence intensities with pos-
itive Nrf2 protein expression as detected by Image-Pro Plus
system are in general in accordance with the quantity/trend
of protein expressionmeasured byWB as previously reported
[21–23].Therefore, we also analyzed the immunofluorescence
intensities of Nrf2 protein expression/staining in glomerular
cells and in tubular epithelial cells, respectively. As shown in
Figures 4 and 5, compared with group M, the expression of
Nrf2 in glomerular cells in groups D1 and D2 was increased,
especially in group D2. Compared with group D2, levels were
lower in groups B1 and B3, while, in group B2, there was no
obvious decrease.
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Figure 3: Levels of Scr and BUN at various groups. (The blood samples were taken from the abdominal aorta 8 h after reperfusion. The data
were represented as mean ± standard deviation (SD), 𝑛 = 8. 󳵳𝑃 < 0.01, △𝑃 < 0.05 versus group S; ◼𝑃 < 0.01 versus group M; X𝑃 < 0.01
versus group D2.)
3.5. Changes of Antioxidants and Oxidants. SOD is an
enzyme which can catalyze breakdown of superoxidants into
oxygen and hydrogen peroxide. GSH can convert hydrogen
peroxide into oxygen and water. Both are the important
antioxidants in the body. MDA is an end-product of lipid
peroxidation in cellmembranes. ∙OH is one of themost active
free radicals. H
2
O
2
is a strong oxidant. All can damage the
cells, leading to cell death or mutations.
3.5.1. Changes of Activity of SOD. As shown in Figure 6(a),
the activity of SOD decreased in group M compared to
group S (𝑃 < 0.01). In groups pretreated with high dose
of Dex (group D2) and ARC239 (group B2), SOD increased
significantly compared to group M (𝑃 < 0.01), while there
was no significant difference in groups D1, B1, and B3 (𝑃 >
0.05).
3.5.2. Changes of Activity of GSH. As shown in Figure 6(b),
the activity of GSH decreased in groupM compared to group
S (𝑃 < 0.01). In groups pretreated with Dex (groups D1, D2)
and ARC239 (group B2), GSH increased significantly com-
pared to group M (𝑃 < 0.01), while there was no significant
difference in groups D1, B1, and B3 (𝑃 > 0.05), compared to
group D2. The level of GSH decreased significantly in group
B1 and group B3 (𝑃 < 0.01). In the kidney, Nrf2 activation
has been shown to play important roles in themaintenance of
GSH levels [24, 25]. However, whether or not and how Nrf2
activation through its targets may regulate GSH have been
largely unknown, which may deserve further study.
3.5.3. Changes of Activity of T-AOC. As shown in Figure 6(c),
the activity of T-AOC decreased significantly in all groups
compared to group S (𝑃 < 0.01). In groups pretreated
with Dex (groups D1, D2) and ARC239 (group B2), it
increased significantly compared to group M (𝑃 < 0.01).
There was no significant difference in groups D1, B1, and B3
(𝑃 > 0.05), compared to group D2. The level of T-AOC
decreased significantly in group B1 and group B3 (𝑃 < 0.01).
3.5.4. Changes of Activity of ∙OH. As shown in Figure 6(d),
the activity of ∙OH increased significantly in all groups
compared to group S (𝑃 < 0.01). In groups pretreated with
Dex (groupsD1, D2) andARC239 (group B2), ∙OHdecreased
significantly compared to group M (𝑃 < 0.01). There was
no significant difference in groups D1, B1, and B3 (𝑃 >
0.05), compared to group D2. The level of ∙OH increased
significantly in group B1 and group B3 (𝑃 < 0.01).
3.5.5. Changes of Activity of H2O2. As shown in Figure 6(e),
the activity of H
2
O
2
increased significantly in all groups
compared to group S (𝑃 < 0.01). In groups pretreated
with Dex (groups D1, D2) and ARC239 (group B2), H
2
O
2
decreased significantly compared to group M (𝑃 < 0.01).
There was no significant difference in groups D1, B1, and
B3 (𝑃 > 0.05), compared to group D2. The level of H
2
O
2
increased significantly in group B1 and group B3 (𝑃 < 0.01).
3.5.6. Changes of Activity of MDA. As shown in Figure 6(e),
the activity of MDA increased significantly in groups M, B1,
and B2, compared to group S (𝑃 < 0.01). In groups pretreated
with high dose of Dex (group D2) and ARC239 (group B2),
MDA decreased significantly compared to group M (𝑃 <
0.01). There was no significant difference in groups D1, B1,
and B3 (𝑃 > 0.05), compared to group D2. The level of MDA
increased significantly in group B1 and group B3 (𝑃 < 0.01).
4. Discussion
Acute kidney injury (AKI) is a severe complication following
OLT. It is the major reason for early postoperation death
and influences the prognosis and rehabilitation of patients.
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Figure 4: The expression of Nrf2 in kidney tissues of different groups was detected by immunofluorescence staining under a laser scanning
confocal microscope (magnification 400x). (a) Group S; (b) group M; (c) group D1; (d) group D2; (e) group B1; (f) group B2; and (g) group
B3. Positive Nrf2 cells were stained green, with the sections counterstained with 4,6-diamidino-2-phenylindole (DAPI) to visualize nuclei.
Arrows indicate Nrf2 positive glomerular cells, while the triangle points at Nrf2 positive tubular epithelial cells.
However the cause of AKI involves multifactors and the
mechanisms contributing to this are still unclear [26, 27].
Our present study used an OALT model which simulates
the key surgical procedures and pathophysiological processes
that occur during liver transplantation, including hemody-
namic changes, congestion, hypoxia, and hepatic ischemia-
reperfusion injury [28–30]. The present study identified that
OALT causes serious injury to the pathological structure in
the kidney 8 h following the procedure [31]. The model was
suitable to investigate the role of Nrf2 in kidney damage after
liver transplantation and evaluate the protective effects of
dexmedetomidine in this pathology.
Oxidative damage that is induced by reactive oxygen
species (ROS) plays an important role in the pathogenesis
of acute kidney injury [32]. Some researchers reported that,
during the state of ischemia and hypoxia, the content of
ATP in kidney cells is decreased, which causes calcium
overload of cells and upregulation of hypoxanthine and
xanthine oxidase.This can affect mitochondrial function and
increase sympathetic tone by generation of large amounts
of free radicals including oxygen free radicals and lipid
free radicals [33, 34]. The free radicals are very active and
increase levels of radicals by chain reaction [35]. The free
radicals will attack cell membrane, protein, DNA or RNA,
and extracellular matrix and change their structure and then
cause multiple organ dysfunction involving kidney damage
[36]. The latter can present as changes in kidney histology
(cell degeneration) and renal failure (increasing Scr and
BUN levels). The current study showed that the increases
in ROS such as MDA, OH, and H
2
O
2
were related to renal
I/R damage. However the correlation between perioperative
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Figure 5: The proportion of Nrf2 positive cells and semiquantitative immunofluorescence of Nrf2 in glomerular cells or tubular epithelial
cells in kidney tissues of different groups. The cells were counted under a laser scanning confocal microscope (magnification 400x). (a) The
proportion of Nrf2 positive cells in tubular epithelial cells; (b) the proportion of Nrf2 positive cells in glomerular cells; (c) semiquantitative
immunofluorescence of Nrf2 in tubular epithelial cells; (d) semiquantitative immunofluorescence of Nrf2 in glomerular cells. Relative
immunofluorescence intensities were normalized to that of group S. The data were represented as mean ± standard deviation (SD), 𝑛 = 8.
󳵳
𝑃 < 0.01 versus group S; ◼𝑃 < 0.05 versus group M; X𝑃 < 0.05 versus group D2.
kidney injury and oxidative stress in liver transplantation
remains unclear [35, 37].
Nrf2 is a transcription factor, which belongs to the
cap “n” collar basic leucine zipper family. It is a major
endogenous antioxidant and is distributed widely in terms
of cells, tissues, and organisms. Under normal conditions,
Nrf2 is repressed by its association with Keap1 which targets
Nrf2 for ubiquitination and proteasomal degradation. Under
conditions of chemical/oxidative stress, Nrf2 evades repres-
sion by Keap1 and accumulates within the nucleus, where it
binds to antioxidant response elements and upregulates the
expression of target genes harboring antioxidant response
elements. It maintains homeostasis [38, 39]. Dexmedetomi-
dine is a highly selective 𝛼
2
adrenergic receptor agonist with
sedative, analgesic, and sympatholytic properties [40]. Many
studies have reported that pretreatment with dexmedetomi-
dine can relieve the kidney I/R damage by inhibiting the
secretion of inflammatory cytokines, decreasing oxidative
stress, and decreasing the numbers of neutrophils in the
kidney [30, 41]. In the current research, we provided evidence
that dexmedetomidine regulates ROS and antioxidation
through Nrf2 and may play an important role in preventing
renal I/R damage. These protective effects were reversed by
a nonspecific 𝛼
2
receptor blocker and a specific 𝛼2A receptor
blocker.
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Figure 6: The antioxidants and oxidants of renal tissue. The data were represented as mean ± standard deviation (SD), 𝑛 = 8. 󳵳𝑃 < 0.01,
△
𝑃 < 0.05 versus group S; ◼𝑃 < 0.01 versus group M; X𝑃 < 0.01 versus group D2.
5. Conclusions
In conclusion, we have found that administration of high
dose dexmedetomidine was associated with a renal pro-
tective effect. We demonstrated that Nrf2 plays a critical
role in decreasing OLT-induced AKI. Pretreatment with
dexmedetomidine upregulated antioxidation and downreg-
ulated oxidation by increasing the expression of Nrf2, ulti-
mately providing a protective effect against AKI after OLT.
The increase in cells and immunofluorescence intensitieswith
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positive Nrf2 protein expression as shown in Figure 5 should
support our notion that activation of Nrf2 may represent
an importantmechanismwhereby dexmedetomidine inhibits
post-OALT kidney injury. However, many questions remain
including what dose of dexmedetomidine provides the best
protection. Further research to explore this subject will be
required.
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